These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32736531)

  • 41. Deleterious vascular effects of indoxyl sulfate and reversal by oral adsorbent AST-120.
    Six I; Gross P; Rémond MC; Chillon JM; Poirot S; Drueke TB; Massy ZA
    Atherosclerosis; 2015 Nov; 243(1):248-56. PubMed ID: 26408929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure.
    Lin CJ; Wu V; Wu PC; Wu CJ
    PLoS One; 2015; 10(7):e0132589. PubMed ID: 26173073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of the Oral Adsorbent AST-120 on Organ-Specific Accumulation of Uremic Toxins: LC-MS/MS and MS Imaging Techniques.
    Sato E; Saigusa D; Mishima E; Uchida T; Miura D; Morikawa-Ichinose T; Kisu K; Sekimoto A; Saito R; Oe Y; Matsumoto Y; Tomioka Y; Mori T; Takahashi N; Sato H; Abe T; Niwa T; Ito S
    Toxins (Basel); 2017 Dec; 10(1):. PubMed ID: 29283413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of indoxyl sulfate with fibroblast growth factor 23 in patients with advanced chronic kidney disease.
    Lin CJ; Pan CF; Chuang CK; Liu HL; Sun FJ; Wang TJ; Chen HH; Wu CJ
    Am J Med Sci; 2014 May; 347(5):370-6. PubMed ID: 24051956
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does Low-Protein Diet Influence the Uremic Toxin Serum Levels From the Gut Microbiota in Nondialysis Chronic Kidney Disease Patients?
    Black AP; Anjos JS; Cardozo L; Carmo FL; Dolenga CJ; Nakao LS; de Carvalho Ferreira D; Rosado A; Carraro Eduardo JC; Mafra D
    J Ren Nutr; 2018 May; 28(3):208-214. PubMed ID: 29439931
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial.
    Akizawa T; Asano Y; Morita S; Wakita T; Onishi Y; Fukuhara S; Gejyo F; Matsuo S; Yorioka N; Kurokawa K;
    Am J Kidney Dis; 2009 Sep; 54(3):459-67. PubMed ID: 19615804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients.
    Lee CT; Hsu CY; Tain YL; Ng HY; Cheng BC; Yang CC; Wu CH; Chiou TT; Lee YT; Liao SC
    Blood Purif; 2014; 37(1):76-83. PubMed ID: 24576840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease.
    Kaminski TW; Pawlak K; Karbowska M; Znorko B; Mor AL; Mysliwiec M; Pawlak D
    Int Urol Nephrol; 2019 Mar; 51(3):491-502. PubMed ID: 30617956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease.
    Dou L; Poitevin S; Sallée M; Addi T; Gondouin B; McKay N; Denison MS; Jourde-Chiche N; Duval-Sabatier A; Cerini C; Brunet P; Dignat-George F; Burtey S
    Kidney Int; 2018 Apr; 93(4):986-999. PubMed ID: 29395338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A; Bhandari S
    Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spherical carbon adsorbent (AST-120) protects deterioration of renal function in chronic kidney disease rats through inhibition of reactive oxygen species production from mitochondria and reduction of serum lipid peroxidation.
    Owada S; Maeba T; Sugano Y; Hirayama A; Ueda A; Nagase S; Goto S; Nishijima F; Bannai K; Yamato H
    Nephron Exp Nephrol; 2010; 115(4):e101-11. PubMed ID: 20424488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremic rats.
    Niwa T; Yazawa T; Ise M; Sugano M; Kodama T; Uehara Y; Maeda K
    Nephron; 1991; 57(1):84-8. PubMed ID: 1904558
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials.
    Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Shimizu M; Shobu Y; Kikuchi M
    BMC Nephrol; 2016 Sep; 17(1):141. PubMed ID: 27716149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Indoxyl sulfate-lowering capacity of oral sorbents affects the prognosis of kidney function and oxidative stress in chronic kidney disease.
    Taki K; Niwa T
    J Ren Nutr; 2007 Jan; 17(1):48-52. PubMed ID: 17198932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LC-MS/MS method for simultaneous determination of serum p-cresyl sulfate and indoxyl sulfate in patients undergoing peritoneal dialysis.
    Shu C; Chen X; Xia T; Zhang F; Gao S; Chen W
    Biomed Chromatogr; 2016 Nov; 30(11):1782-1788. PubMed ID: 27129599
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.
    Kamiński TW; Pawlak K; Karbowska M; Myśliwiec M; Pawlak D
    BMC Nephrol; 2017 Jan; 18(1):35. PubMed ID: 28122514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120.
    Niwa T
    Ther Apher Dial; 2011 Apr; 15(2):120-4. PubMed ID: 21426500
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between indoxyl sulfate and bone histomorphometry in pre-dialysis chronic kidney disease patients.
    Barreto FC; Barreto DV; Canziani ME; Tomiyama C; Higa A; Mozar A; Glorieux G; Vanholder R; Massy Z; de Carvalho AB
    J Bras Nefrol; 2014; 36(3):289-96. PubMed ID: 25317610
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β
    Yamamoto S
    Clin Exp Nephrol; 2019 Feb; 23(2):151-157. PubMed ID: 29869756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral adsorbents for preventing or delaying the progression of chronic kidney disease.
    Wu HM; Sun HJ; Wang F; Yang M; Dong BR; Liu GJ
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007861. PubMed ID: 25317905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.